老君仙灵芝口服液配合化疗治疗中晚期非小细胞性肺癌临床观察  

Effect of Laojunxian Lingzhi Oral Liquid Combined with Chemotherapy on Non_parvicellular Lung Cancer at Stages Ⅱ and Ⅲ

作　　者：焉本魁[1,2] 魏延菊 李育强[1,2] 

机构地区：[1]青岛市立医院 [2]青岛医学院第二附属医院

出　　处：《中药新药与临床药理》1998年第2期78-80,共3页Traditional Chinese Drug Research and Clinical Pharmacology

摘　　要：运用老君仙灵芝口服液配合化疗治疗中晚期非小细胞性肺癌，随机分成治疗组（３５例）和对照组（２１例），有效率分别为６５．７１％和４２．８５％（Ｐ＜０．０１）。观察结果表明老君仙灵芝口服液能够减轻化疗毒副作用，提高化疗治疗效果，能改善肿瘤患者生活质量。能减少化疗对骨髓造血功能的抑制，使化疗前后白细胞和血小板无明显减少，提高肿瘤患者被抑制的细胞免疫功能，对Ｔ细胞有促进作用。从而提高了患者特异性免疫杀伤力。Fifty_six patients with non-parvicellular lung cancer at stages Ⅱ and Ⅲ were allocated randomly to two groups to study the effect of Laojunxian Lingzhi Oral Liquid(LJXLZ) combined with chemotherapy. The effective rates were 65.71% and 42.55% in the treatment group and the control group respectively(P<0.01). These results show that LJXLZ can decreased the toxic and side effects and enhance the therapeutic effect of chemotherapy and improve the quality of life. It is also suggested that the suppression of hemotopoietic function of bone marrow by chemotherapy is lessened, the cellular immune function is echanced, and the inhibitory cellular immune function is improved.

关 键 词：口服液 非小细胞肺癌 肺癌 中医药疗法 

分 类 号：R734.205[医药卫生—肿瘤]